company background image
DSGN

Design TherapeuticsNasdaqGS:DSGN Stock Report

Market Cap

US$922.4m

7D

-6.1%

1Y

n/a

Updated

07 Dec, 2021

Data

Company Financials +
DSGN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

DSGN Stock Overview

Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions.

Price History & Performance

Summary of all time highs, changes and price drops for Design Therapeutics
Historical stock prices
Current Share PriceUS$16.70
52 Week HighUS$50.50
52 Week LowUS$12.52
Beta0
1 Month Change-6.91%
3 Month Change-5.11%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-59.75%

Recent News & Updates

Dec 03
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Aug 18
Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation

Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Jun 07

Design Therapeutics expands board of directors

Design Therapeutics (DSGN) announces the appointments of industry veterans, Heather Behanna and Deepa Prasad to its board of directors effective June 15, 2021.Behanna currently serves as a principal at SR One Capital Management, concentrating on early-stage innovative therapeutic opportunities.Prasad currently serves as a managing director at WestRiver Group ((WRG)), where she leverages her more than 20 years of investing and operating experience to focus on investments in healthcare innovation across biotech and digital health and artificial intelligence.

Shareholder Returns

DSGNUS BiotechsUS Market
7D-6.1%-7.0%-2.6%
1Yn/a-3.7%17.8%

Return vs Industry: Insufficient data to determine how DSGN performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how DSGN performed against the US Market.

Price Volatility

Is DSGN's price volatile compared to industry and market?
DSGN volatility
DSGN Average Weekly Movement9.0%
Biotechs Industry Average Movement8.9%
Market Average Movement6.2%
10% most volatile stocks in US Market14.8%
10% least volatile stocks in US Market2.4%

Stable Share Price: DSGN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: DSGN's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201733João Sifferthttps://www.designtx.com

Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich’s ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy. The company was incorporated in 2017 and is based in Carlsbad, California.

Design Therapeutics Fundamentals Summary

How do Design Therapeutics's earnings and revenue compare to its market cap?
DSGN fundamental statistics
Market CapUS$922.38m
Earnings (TTM)-US$28.32m
Revenue (TTM)US$33.00k

Over9,999x

P/S Ratio

-32.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DSGN income statement (TTM)
RevenueUS$33.00k
Cost of RevenueUS$20.15m
Gross Profit-US$20.12m
ExpensesUS$8.21m
Earnings-US$28.32m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.51
Gross Margin-60,957.58%
Net Profit Margin-85,827.27%
Debt/Equity Ratio0%

How did DSGN perform over the long term?

See historical performance and comparison

Valuation

Is Design Therapeutics undervalued compared to its fair value and its price relative to the market?

2.36x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate DSGN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate DSGN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: DSGN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: DSGN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DSGN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DSGN is good value based on its PB Ratio (2.4x) compared to the US Biotechs industry average (2.6x).


Future Growth

How is Design Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-9.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DSGN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DSGN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DSGN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: DSGN is forecast to have no revenue next year.

High Growth Revenue: DSGN is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DSGN's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Design Therapeutics performed over the past 5 years?

-321.9%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: DSGN is currently unprofitable.

Growing Profit Margin: DSGN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if DSGN's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare DSGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DSGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: DSGN has a negative Return on Equity (-7.23%), as it is currently unprofitable.


Financial Health

How is Design Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: DSGN's short term assets ($395.3M) exceed its short term liabilities ($5.5M).

Long Term Liabilities: DSGN's short term assets ($395.3M) exceed its long term liabilities ($3.3M).


Debt to Equity History and Analysis

Debt Level: DSGN is debt free.

Reducing Debt: DSGN had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DSGN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: DSGN has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 105.2% each year


Dividend

What is Design Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DSGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DSGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DSGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DSGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DSGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.9yrs

Average management tenure


CEO

João Siffert (58 yo)

1.17yrs

Tenure

US$4,726,094

Compensation

Dr. João Siffert, MD, is Chief Executive Officer and Director at Design Therapeutics, Inc since October 2020 and its President since January 2021. From August 2011 to April 2016, he served as Chief Medical...


CEO Compensation Analysis

Compensation vs Market: João's total compensation ($USD4.73M) is above average for companies of similar size in the US market ($USD2.35M).

Compensation vs Earnings: Insufficient data to compare João's compensation with company performance.


Leadership Team

Experienced Management: DSGN's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: DSGN's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: DSGN only recently listed within the past 12 months.


Top Shareholders

Company Information

Design Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Design Therapeutics, Inc.
  • Ticker: DSGN
  • Exchange: NasdaqGS
  • Founded: 2017
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$922.376m
  • Shares outstanding: 55.23m
  • Website: https://www.designtx.com

Number of Employees


Location

  • Design Therapeutics, Inc.
  • 6005 Hidden Valley Road
  • Suite 110
  • Carlsbad
  • California
  • 92011
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/07 00:37
End of Day Share Price2021/12/06 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.